SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-033087
Filing Date
2024-03-11
Accepted
2024-03-11 17:24:24
Documents
16
Period of Report
2024-03-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm248477d1_8k.htm   iXBRL 8-K 32500
2 EXHIBIT 10.1 tm248477d1_ex10-1.htm EX-10.1 226262
  Complete submission text file 0001104659-24-033087.txt   535429

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aktx-20240311.xsd EX-101.SCH 3541
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aktx-20240311_def.xml EX-101.DEF 26894
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aktx-20240311_lab.xml EX-101.LAB 36553
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aktx-20240311_pre.xml EX-101.PRE 25518
18 EXTRACTED XBRL INSTANCE DOCUMENT tm248477d1_8k_htm.xml XML 5366
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 24739207
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)